MLYS vs. RARE, ACLX, PTGX, AAPG, SRRK, MTSR, KYMR, VKTX, MOR, and CRNX
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Ultragenyx Pharmaceutical (RARE), Arcellx (ACLX), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), Metsera (MTSR), Kymera Therapeutics (KYMR), Viking Therapeutics (VKTX), MorphoSys (MOR), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.
Mineralys Therapeutics vs. Its Competitors
Mineralys Therapeutics (NASDAQ:MLYS) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
Mineralys Therapeutics has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -93.04%. Mineralys Therapeutics' return on equity of -71.15% beat Ultragenyx Pharmaceutical's return on equity.
Mineralys Therapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.
In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 6 mentions for Ultragenyx Pharmaceutical and 3 mentions for Mineralys Therapeutics. Ultragenyx Pharmaceutical's average media sentiment score of 0.77 beat Mineralys Therapeutics' score of 0.62 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.
84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 33.2% of Mineralys Therapeutics shares are owned by insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Mineralys Therapeutics presently has a consensus price target of $32.25, indicating a potential upside of 138.36%. Ultragenyx Pharmaceutical has a consensus price target of $87.00, indicating a potential upside of 139.27%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Mineralys Therapeutics.
Mineralys Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Ultragenyx Pharmaceutical beats Mineralys Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLYS) was last updated on 6/30/2025 by MarketBeat.com Staff
